Stockscreener 앱 받기
49.81
15.84%
6.81
시간 외 거래:
52.00
2.19
+4.40%
전일 마감가:
$43.00
열려 있는:
$43.5
하루 거래량:
22.11M
Relative Volume:
1.95
시가총액:
$19.46B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-5.7056
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
+22.75%
1개월 성능:
+47.37%
6개월 성능:
+60.83%
1년 성능:
+38.79%
1일 변동 폭
$43.34
$50.00
1주일 범위
$39.25
$50.00
52주 변동 폭
$22.28
$50.00
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.81 | 16.80B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.14 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.33 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.37 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
365.46 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.64 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-12 | 개시 | Jefferies | Hold |
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Moderna Inc.: From Pandemic Breakout Star to Platform Powerhouse - AD HOC NEWS
Moderna Stock Soars 16%, Hits 52-Week High as "mRNA 2.0" Cancer Vaccine Data Stuns Markets - FXLeaders
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
Intel, Moderna, TMC, Microsoft And Lucid: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Moderna (MRNA) Shares Surge 15.84% on Positive Skin Cancer Vaccine Trial Results with Merck - Intellectia AI
Why Moderna Stock Surged Today - Yahoo Finance
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
U.S. Markets Rose Wednesday; Moderna Led Increases - Barron's
Moderna and Merck pop on cancer vaccine, Lucid-Rockwell partnership - Yahoo Finance
Moderna Stock Rallies as Oncology Results Improve the Platform’s Value Case - Investing.com
Moderna Stock Skyrockets To 52-Week High: What's Behind The Surge? - Benzinga
Moderna (NASDAQ:MRNA) Sets New 1-Year HighWhat's Next? - MarketBeat
Moderna (MRNA) Shares Skyrocket, What You Need To Know - Finviz
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
Moderna’s Strategic Growth Propels Stock Upwards - StocksToTrade
Growth Recap: How volatile is Moderna Inc stockJuly 2025 Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
Why Is Moderna (MRNA) Stock Up Today: Merck Partnered Vaccine Cuts Recurrence Risk - Tokenist
Moderna stock hits 52-week high at $45.44 By Investing.com - Investing.com Australia
Moderna stock hits 52-week high at $45.44 - Investing.com
The Truth About Moderna Inc: Is MRNA Still a Pandemic One-Hit Wonder or a Silent Beast? - AD HOC NEWS
Sumitomo Mitsui Trust Group Inc. Reduces Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Cancer Data Sparks Questions On Oncology Pivot And Stock Valuation - simplywall.st
BofA Raises Moderna Price Target to $27, Maintains Underperform Rating - Intellectia AI
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious - Stocktwits
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Merck/Moderna Intismeran Data Show Continued Efficacy In Melanoma - Citeline News & Insights
Moderna–Merck Cancer Vaccine Shows Durable Benefit At 5 Years In High-Risk Melanoma - Benzinga
Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up - Reuters
Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High? - MarketBeat
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play - TechStock²
Moderna's Options: A Look at What the Big Money is Thinking - Benzinga
Moderna, Merck’s skin cancer vaccine shows sustained benefit in long-term follow-up - whtc.com
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update - Stocktwits
Moderna rises as cancer vaccine shows long-term benefit in melanoma study - TradingView — Track All Markets
New personalized skin cancer treatment shows success in preventing return of melanoma - The Independent
Moderna and Merck confirm the lasting effectiveness of their skin cancer vaccine - marketscreener.com
Moderna and Merck report 5-year data for intismeran autogene - The Pharma Letter
Intismeran Autogene + KEYTRUDA Improves 5-Year Recurrence-Free Survival In Melanoma, Moderna & Merck - Nasdaq
Moderna's (MRNA) Cancer Therapy Shows Promising Results in Late-Stage Trial - GuruFocus
Moderna, Merck Report Positive Results From Cancer-Vaccine Study - The Wall Street Journal
Moderna cancer therapy with Merck’s Keytruda cut mortality by 49% in mid-stage trial - Seeking Alpha
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Compl - Investing News Network
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melano - ACCESS Newswire
Moderna, Merck Show Long-Term Survival for mRNA-Keytruda Combo - BioSpace
Moderna and Merck report sustained melanoma treatment benefits at 5 years - StreetInsider
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy UpdatesFDL Reporter | The Reporter - fdlreporter.com
Moderna Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - indeonline.com
Moderna (MRNA) Valuation Check After Raised 2025 Outlook And Cost Cuts At JPMorgan Conference - Yahoo Finance
Moderna Shares Surge Amid Positive Earnings and Regulatory News - StocksToTrade
Moderna’s Market Gains as Revenue Projections Boost Investor Confidence - timothysykes.com
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.17%
4.40%
자본화:
|
볼륨(24시간):